An interventional study of skin biopsy in Amyotrophic Lateral Sclerosis, sponsored by Institut Pasteur. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-01.
Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science
Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris.
The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology.
iPS (induced pluripotent stem cells) and then differentiated cells will be generated.
The pathophysiology of ALS will be studied on the 3 types of cells (fibroblasts, iPS, differentiated cells).
717 studies on the registry are indexed under Motor Neuron Disease; 137 are open to participants now.
This study's enrollment of 19 is below the median of 35 across 461 interventional studies indexed under Motor Neuron Disease.
Browse Motor Neuron Disease studies →Institut Pasteur is the lead sponsor of 96 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: skin biopsy
biopsy 5mm maximum on healthy skin under local anaesthesia.
Success of fibroblast culture, amplification, and freezing pellets
Time frame: 2 months
Induced pluripotent Stem Cells generation success
Time frame: 2 years
neurones, motoneurones, glial cells obtention from fibroblasts or iPS
Time frame: 2 years
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Pasteur